AR057086A1 - Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto - Google Patents

Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto

Info

Publication number
AR057086A1
AR057086A1 ARP060103244A ARP060103244A AR057086A1 AR 057086 A1 AR057086 A1 AR 057086A1 AR P060103244 A ARP060103244 A AR P060103244A AR P060103244 A ARP060103244 A AR P060103244A AR 057086 A1 AR057086 A1 AR 057086A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
optionally substituted
nririi
alkoxy
Prior art date
Application number
ARP060103244A
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Bruce Schnicker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057086(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057086A1 publication Critical patent/AR057086A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere además un composiciones farmacéuticas que contienen tales compuestos; aptos para su utilizacion en medicamentos para la dismenorrea, hipertension, fallo cardíaco cronico, secrecion inapropiada de vasopresina, cirrosis hepática, síndrome nefrítico, trastorno obsesivo-compulsivo, trastornos de ansiedad y depresion; y un métodos para la obtencion de los mismos. Reivindicacion 1: Un compuesto de la formula general (1), en la que: R1 es H, o es alquilo C1-6 sustituido por CN, alcoxi C1-6, OH, halogeno, o por NRiRii, o es alquilo C2-6; o es arilo, heteroarilo o sulfonilo de 5 o 6 eslabones, sustituidos opcionalmente una o varias veces por B; o es -(CH2)m-Ra, en el que Ra es: CN; ORi; NRiRii; cicloalquilo C3-6, heterocicloalquilo de 4 un 7 eslabones, arilo, o heteroarilo de 5 o 6 eslabones que están opcionalmente sustituidos una o varias veces por B; o es -(CH2)n-(CO)-Rb o -(CH2)n-(SO2)-Rb, en los que Rb es: alquilo C1-6; alcoxi C1-6; cicloalquilo C3-6, -(CH2)m-NRiiiRiv; NRiRii; cicloalquilo C3-6, heterocicloalquilo de 4 un 7 eslabones, arilo, o heteroarilo de 5 o 6 eslabones que están opcionalmente sustituidos una o varias veces por B; o R1 y R3 junto con el anillo indol al que están unidos forman un heterocicloalquilo de 5 o 6 eslabones que puede estar sustituido por =O, C(O)O-alquiloC1-6 o alquilo C1-6; R2 es uno o varios de H, OH, halogeno, CN, nitro, alcoxi C1-6, -O-CH2-alqueniloC2-6, benciloxi, haloalcoxi C1-6, alquilo C1-6 opcionalmente sustituido por-NRiiRiv o halogeno, o dos R2 pueden formar un puente oxo o dioxo junto con el anillo indol al que están unidos; R3 es H; o es F; o es -(CO)-Rc, en el que Rc es: alquilo C1-6; -(CH2)nNRiRii; -(CH2)n-NRiiiRiv; heterocicloalquilo de 5 o 6 eslabones opcionalmente sustituido por alquilo C1-6; o es alquilo C1-6 está opcionalmente sustituido por halogeno; NRiRii, NRiRiv; -O(CO)-alquiloC1-6, o por-NH(CO)Rd, en el que Rd es alquilo C1-6 opcionalmente sustituido por halogeno o nitro, o Rd es arilo o un heteroarilo de 5 o 6 eslabones, que están opcionalmente sustituidos por halogeno, nitro, alquilo C1-6 o haloalquilo C1-6; A se elige entre el grupo formado por las formulas (2) un (6), en los que: R4 es - NH(CO)Re, en el que Re es alcoxi C1-6 o arilo opcionalmente sustituido por halogeno; o es alcox C1-6, CN; o es arilo, heteroarilo de 5 o 6 eslabones, bencilo, ariloxi o un anillo heteroarilo bicíclico de 9 a 10 eslabones, que están opcionalmente sustituidos por CN, halogeno, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, nitro, hidroxilo, NRiRii, NRiiiRiv, alcoxiC1-6-alquilenoC1-6, S(O)2-alquiloC1-6, haloalcoxi C1-6, o por un puente oxo o dioxo; y R5 es H, OH, CN, COORiii o CONRiiiRiv; R6 es alquilo C2-6; o es -C(O)-Rf, en el que Rf es un grupo arilo sustituido por halogeno, alcoxi C1-6, o CN; o es arilo, heteroarilo de 5 o 6 eslabones, o un anillo heteroarilo bicíclico de 9 a 10 eslabones que están opcionalmente sustituido por halogeno, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, CN, nitro, NRiRii , NRiiiRiv, alcoxiC1-6-alquilenoC1-6, COOH, S(O)2-alquiloC1-6, hidroxilo, haloalcoxiC1-6, o por un puente oxo o dioxo; o es bencilo sustituido por halogeno, alquiloC1-6, haloalquiloC1-6 o por un puente oxo o dioxo; B es halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN, halogeno o alcoxi C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O)O-alquiloC1-6, - C(O)NRiRii, -C(O)- alquiloC1-6, -S(O)2-alquiloC1-6, -S(O)2-NRiRii, (CriiiRiv)n-fenilo, o (CRiiiRiv)n-heteroarilo de 5 o 6 eslabones, en el que el fenilo o el resto heteroarilo de 5 o 6 eslabones están opcionalmente sustituidos por uno o varios sustituyentes elegidos entre el grupo formado por: halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN o alcoxi C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O)O-alquiloC1-6, -C(O)-NRiRii, -C(O)-alquiloC1-6, -S(O)2-alquiloC1-6, -S(O)2-NRiRii; Ri y Rii son H, alquilo C1-6, alquilC1-6-NRiiiRiv, -(CO)O-alquiloC1-6, -C(O)-NRiiiRiv, -C(O)-alquiloC1-6, -S(O)2-alquiloC1-6 o -S(O)2-NRiiiRiv; Riii y Riv son H o alquilo C1-6; m es numero de 1 a 6; n es numero de 0 a 4; así como las sales farmacéuticamente aceptables del mismo.
ARP060103244A 2005-07-29 2006-07-27 Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto AR057086A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107044 2005-07-29
EP05111072 2005-11-22

Publications (1)

Publication Number Publication Date
AR057086A1 true AR057086A1 (es) 2007-11-14

Family

ID=37442112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103244A AR057086A1 (es) 2005-07-29 2006-07-27 Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto

Country Status (15)

Country Link
US (3) US7781436B2 (es)
EP (2) EP2392571A3 (es)
JP (1) JP2009502859A (es)
KR (1) KR101020351B1 (es)
CN (1) CN102295636A (es)
AR (1) AR057086A1 (es)
AU (1) AU2006274884B2 (es)
BR (1) BRPI0614692A2 (es)
CA (1) CA2616937A1 (es)
IL (1) IL188928A0 (es)
MX (1) MX2008001292A (es)
NO (1) NO20080316L (es)
RU (1) RU2422442C2 (es)
TW (1) TWI314147B (es)
WO (1) WO2007014851A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659412A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
ATE527249T1 (de) * 2006-12-08 2011-10-15 Hoffmann La Roche Indole
PE20081401A1 (es) 2006-12-28 2008-10-24 Hoffmann La Roche Derivados de indol como antagonistas de receptores vasopresina
PA8782701A1 (es) 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii
RU2387642C2 (ru) 2007-10-31 2010-04-27 Общество С Ограниченной Ответственностью "Бинатех" Производные 5-замещенных индол-3-карбоновой кислоты, обладающие противовирусной активностью, способ их получения и применение
MY153609A (en) * 2008-01-31 2015-02-27 Sanofi Aventis Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
JP2011529966A (ja) * 2008-08-02 2011-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ウロテンシンｉｉ受容体拮抗物質
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
US9981942B2 (en) * 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
DK3137168T3 (da) 2014-04-30 2022-03-21 Univ Columbia Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US543169A (en) * 1895-07-23 Self-measuring liquid-tank
US2694700A (en) 1950-01-21 1954-11-16 Peter L Shanta Process of suspension polymerization
GB1305458A (es) * 1969-02-26 1973-01-31
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4443242A (en) 1981-01-21 1984-04-17 Reckitt & Colman Products Limited Foliar feed
US4544657A (en) 1983-05-19 1985-10-01 Hoffmann-La Roche Inc. Substituted isoquinolines
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
JPH03161470A (ja) 1989-11-17 1991-07-11 Nisshin Flour Milling Co Ltd インドール誘導体
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
FR2696177B1 (fr) * 1992-09-28 1995-05-12 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
DK0863875T3 (da) 1995-09-07 2003-12-01 Hoffmann La Roche Hidtil ukendte 4-(oxyalkoxyphenyl)-3-oxy-piperiner til behandling af hjerte- og nyrelidelser
GB9609374D0 (en) 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
ATE296801T1 (de) 1996-06-28 2005-06-15 Meiji Seika Kaisha Tetrahydrobezindol derivate
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
WO1999055318A1 (en) 1998-04-29 1999-11-04 Choongwae Pharm. Co., Ltd. Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
US6326381B1 (en) 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
EP1243268A4 (en) 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd MEDICINAL COMPOSITION
JP2001278872A (ja) 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
DE60200061T2 (de) 2001-01-18 2004-07-08 Alps Electric Co., Ltd. Drehverbinder
CN1250544C (zh) 2001-02-07 2006-04-12 奥索-麦克尼尔药品公司 吡啶并芳基苯基噁唑烷酮抗菌剂和相关组合物及方法
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
WO2003037862A1 (fr) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Derives amide, et medicaments correspondants
ATE468339T1 (de) 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
WO2003101964A1 (fr) * 2002-05-31 2003-12-11 Takeda Pharmaceutical Company Limited Derive piperidine, procede de production, et utilisation
TW200402417A (en) * 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
DK1581492T3 (da) 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
AP2331A (en) * 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
JP4734119B2 (ja) 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
CN101018770A (zh) 2004-04-07 2007-08-15 千禧药品公司 炎性疾病治疗用pgd2受体拮抗剂
US20070254877A1 (en) 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
KR100984893B1 (ko) * 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체

Also Published As

Publication number Publication date
US20070027163A1 (en) 2007-02-01
KR101020351B1 (ko) 2011-03-08
KR20080027897A (ko) 2008-03-28
JP2009502859A (ja) 2009-01-29
AU2006274884B2 (en) 2012-04-05
RU2422442C2 (ru) 2011-06-27
WO2007014851A2 (en) 2007-02-08
WO2007014851A3 (en) 2007-05-31
TW200740790A (en) 2007-11-01
TWI314147B (en) 2009-09-01
BRPI0614692A2 (pt) 2009-05-19
NO20080316L (no) 2008-02-13
RU2008101962A (ru) 2009-09-10
CA2616937A1 (en) 2007-02-08
EP2392571A2 (en) 2011-12-07
CN102295636A (zh) 2011-12-28
US20100222357A1 (en) 2010-09-02
US20120040990A1 (en) 2012-02-16
MX2008001292A (es) 2008-03-25
EP1917255A2 (en) 2008-05-07
US7781436B2 (en) 2010-08-24
IL188928A0 (en) 2008-08-07
AU2006274884A1 (en) 2007-02-08
EP2392571A3 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
AR057086A1 (es) Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto
AR059136A1 (es) Derivados de indol-3-il-carbonil-espiro-piperidina
AR054830A1 (es) Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1a
AR060173A1 (es) Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc.
AR056188A1 (es) Derivados indol-3-il-carbonil-piperidin-benzoimidazol como antagonistas del receptor v1a
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR048302A1 (es) DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR048413A1 (es) Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR072227A1 (es) Derivados de triazinona sustituidos
ES2552320T3 (es) Nuevas piridín-2-onas y piridazín-3-onas sustituidas
AR072824A1 (es) Derivados de piridina con accion antivirica
AR047903A1 (es) Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
AR047902A1 (es) Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c
AR046758A1 (es) Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR051215A1 (es) Derivados de quinazolina
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal